Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06625320
Title Phase 3 Study of RMC-6236 in Patients with Previously Treated Metastatic Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) (RASolute 302)
Acronym RASolute 302
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Revolution Medicines, Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST